secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2026-08-13T20:03:21+00:00
Accession:  0001493152-26-037739
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q2 net loss narrows to $6.3M; FDA 510(k) submitted for Flu/RSV test
--------------------------------------------------------------------------------

- Revenue $0.17M vs $0.16M YoY; net loss $6.3M ($1.46/share) vs $7.7M ($7.00) prior year.
- Operating loss $6.2M, improved from $8.1M; adjusted EBITDA loss $5.8M vs $7.2M; cash $3.6M.
- Submitted FDA 510(k) for Flu A/B & RSV test on PCR Pro; clinical study 1,400+ patients, 27 analytical studies, 10,000+ runs.
- Advanced Saudi manufacturing: industrial site approval and lease in Sudair Industrial City; distribution agreement in Mexico.
- Appointed Wes Lindsey, Ph.D. as Chief Scientific Officer; initiated TB studies in India via CoSara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226037739/0001493152-26-037739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226037739/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer